QGEN — QIAGEN N.V.

NYSE · Health Care · Biotechnology · CIK 1015820 · Netherlands
Last close
$41.40
Market Cap
$8.54B
52W High
$44.03
52W Low
$32.24
ADV30
2,848,786
Next earnings
2026-08-05
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 492,320,000 309,603,000 116,626,000 68,043,000 5,782,065,000 646,289,000 2,450,359,000
Dec 2025 540,420,000 325,269,000 121,880,000 107,829,000 6,281,232,000 839,005,000 2,503,078,000
Sep 2025 532,583,000 331,259,000 137,293,000 130,043,000 6,553,497,000 1,355,594,000 2,904,082,000
Jun 2025 533,540,000 334,286,000 135,974,000 96,250,000 5,823,758,000 733,815,000 2,318,268,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$654,326,000
Investing CF
$-305,279,000
Financing CF
$-178,976,000
CapEx
$-207,126,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$2.04
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$2,748,390,000
Inventory
$301,888,000
Receivables
$520,033,000
ST Investments
$259,913,000
EBIT TTM
$523,521,000
Pretax Income TTM
$490,265,000
Interest Exp TTM
$33,256,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,098,862,976
EBITDA
$727,684,992
Free Cash Flow
$238,874,368
Enterprise Value
$9,569,836,032
Total Cash
$646,289,024
Total Debt
$1,667,063,040
Shares Out
206,250,000
Trailing EPS
$1.96
Book Value
$16.15
ROE
11.9%
ROA
6.0%
Div Yield
0.84%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,089,999,000 520,310,000 424,880,000 6,281,232,000 2,503,078,000 654,326,000
Dec 2024 1,978,214,000 199,899,000 83,591,000 5,689,622,000 2,122,283,000 673,551,000
Dec 2023 1,965,311,000 445,247,000 341,303,000 6,115,190,000 2,307,426,000 459,455,000
Dec 2022 2,141,518,000 576,228,000 423,211,000 6,287,735,000 2,821,124,000 715,264,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$2.62

Max Pain — expiry 2026-08-21

max pain strike: $40.00 · spot: $41.40 · call oi: 75,232 · put oi: 5,776
Expected Move to 2026-08-21: ±$6.10 (14.73%) — implied range $35.30$47.50 · ATM straddle on $40.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KYMR Kymera Therapeutics, Inc. $8.51B $103.40
APGE Apogee Therapeutics, Inc. $8.27B $134.09
RGEN REPLIGEN CORP $7.96B $141.01
IMVT Immunovant, Inc. $7.93B $38.62
PCVX Vaxcyte, Inc. $7.81B $54.08

News headlines (Yahoo Finance, 1h cache)

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2026-07-30 14:00 · Yahoo
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
2026-07-29 14:00 · Yahoo
Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network
2026-07-29 12:00 · Yahoo
[Latest] Global Precision Diagnostics And Medicine Market Size/Share Worth USD 345.75 Billion by 2035 at a 8.91% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Seg
2026-07-28 17:30 · Yahoo
KKR (KKR) After Qiagen Interest And Allyntra Launch Has Valuation Back In Focus
2026-07-23 08:12 · Yahoo
KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen
2026-07-22 19:11 · Yahoo
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate
2026-07-17 10:44 · Yahoo
QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak
2026-07-15 20:05 · Yahoo
QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast
2026-07-15 12:48 · Yahoo
QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe
2026-07-14 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.